This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernier, J. Articles by Cooper, J. S. Search for Related Content PubMed PubMed Citation Articles by Bernier, J. Articles by Cooper, J. S.

Original Paper Head and Neck Cancers

Chemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence?

^a Department of Radiation Oncology, Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland; ^b Department of Radiation Oncology, Maimonides Medical Center, Brooklyn, New York, USA

Correspondence: J. Bernier, M.D., Department of Radiation Oncology, Oncology Institute of Southern Switzerland, San Giovanni Hospital, CH-6504 Bellinzona, Switzerland. Telephone: 41-91-811-9157; Fax: 41-91-811-8678; e-mail: jacques.bernier{at}hcuge.ch

Patients with locally advanced, operable head and neck squamous cell carcinoma (HNSCC) are known to be at high risk of treatment failure, ranging from local regrowth to lymphatic spread to systemic dissemination. Attacking specifically each of these patterns of failure implies the use of a multimodal approach. Throughout the past two decades the management of stages III/IV HNSCC remained a matter of debate, especially with regards to treatment intensity and sequencing. Surgery and/or radiotherapy were the mainstay of local-regional treatment in patients with locally advanced disease, but treatment outcome often remained disappointing. In the hope of improving the prognosis after radical surgery, cisplatin-based combinations have been administered before surgery, in the interval between surgery and radiotherapy, or after radiotherapy. Until very recently these combinations, at best, decreased systemic failures without having a real impact on local outcome or survival. Indeed, until the mid-1990s, most trials that had tested postoperative combinations of chemotherapy and radiotherapy did not show any significant benefit. In 2004 level I evidence was established with the publication of the results of two large-scale, independent but similar trials conducted in Europe and the U.S. Both studies demonstrated that, compared with postoperative irradiation alone, adjuvant concurrent chemoradiation was more efficacious in terms of local-regional control and disease-free survival. With the publication of these two trials the evidence demonstrating the potential value of concurrent postoperative chemoradiotherapy in high-risk operable head and neck cancer is strong; however, additional studies and comparative analysis of the selection criteria and treatment outcomes across these two trials will be needed to gain a more accurate assessment of benefit and risk levels in specific patients with operable, locally advanced disease.

Key Words. Squamous cell carcinoma • Head and neck • Surgery • Radiotherapy • Chemotherapy • Chemoradiation

This article has been cited by other articles:

				J. H. Gibcus, L. Menkema, M. F. Mastik, M. A. Hermsen, G. H. de Bock, M.-L. F. van Velthuysen, R. P. Takes, K. Kok, C. A. Alvarez Marcos, B. F.A.M. van der Laan, et al. Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6257 - 6266. [Abstract] [Full Text] [PDF]

				J. Bernier, J. B. Vermorken, and W. M. Koch Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer J. Clin. Oncol., June 10, 2006; 24(17): 2629 - 2635. [Abstract] [Full Text] [PDF]

				M. R. Posner Adjuvant Post-Operative Chemoradiotherapy In Head and Neck Cancer: A Standard Of Care? Oncologist, March 1, 2005; 10(3): 174 - 175. [Full Text] [PDF]